ADOCIA Reports Second Quarter 2024 Financial Results and Provides a Business Update
Cash position of €10.3 million as of June 30, 2024 Continuation of partnership discussions on M1Pram with Sanofi BioChaperone® Lispro Phase 3 study is on track for completion in December, milestone associated with a payment of $10 million Post-period …